Previous 10 | Next 10 |
Image source: The Motley Fool. Chiasma Inc (NASDAQ: CHMA) Q4 2019 Earnings Call Mar 16, 2020 , 5:00 p.m. ET Operator Continue reading
Chiasma, Inc. (CHMA) Q4 2019 Earnings Conference Call March 16, 2020 05:00 p.m. ET Company Representatives Raj Kannan - Chief Executive Officer Bill Ludlam - Senior VP of Clinical Development & Medical Affairs Mark Fitzpatrick - President Dawn Schottlandt - VP, IR & Cor...
Chiasma (NASDAQ: CHMA ): Q4 GAAP EPS of -$0.29 misses by $0.06 . More news on: Chiasma, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
MYCAPSSA ® PDUFA Date Set for June 26, 2020; U.S. Commercial Launch Planned in Q4’20 First Industry Sponsored U.S. Disease State Registry for Acromegaly Began Enrolling Patients NEEDHAM, Mass., March 16, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clini...
NEEDHAM, Mass., March 09, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today announced that it will host a conference call and live audio webcast on...
The FDA accepts for review Chiasma's ( CHMA +1.3% ) resubmitted marketing application for Mycapssa (octreotide) for the maintenance treatment of adults with acromegaly. More news on: Chiasma, Inc., Healthcare stocks news, Read more ...
FDA sets PDUFA date of June 26, 2020 Acceptance follows December 26, 2019 NDA resubmission NEEDHAM, Mass., Jan. 13, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chr...
Thinly traded micro cap Chiasma (NASDAQ: CHMA ) perks up 4% premarket on light volume on the heels of its corporate update and 2020 expected milestones. More news on: Chiasma, Inc., Healthcare stocks news, Stocks on the move, Read more ...
MYCAPSSA ® NDA resubmitted to FDA; PDUFA decision expected mid-2020 MYCAPSSA ® U.S. commercial launch planned for the fourth quarter of 2020 Top-line MYCAPSSA ® MPOWERED Phase 3 results on track for the fourth quarter of 2020 NEEDHAM, Mass., Jan. 10, 20...
NEEDHAM, Mass., Dec. 19, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today announced that it has been selected for addition to the NASDAQ Biotechnology In...
News, Short Squeeze, Breakout and More Instantly...
Pulmatrix appoints Director Anand Varadan PR Newswire LEXINGTON, Mass. , July 27, 2021 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and...
NEEDHAM, Mass., June 28, 2021 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), (“Chiasma” or the “Company”), a commercial-stage biopharmaceutical company utilizing its delivery platform technology to develop and commercialize oral therapies to improve the lives ...
NEEDHAM, Mass., May 27, 2021 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), (“Chiasma” or the “Company”) today presented patient-reported outcomes (PROs) data from its MPOWERED™ Phase 3 trial demonstrating that study patients with acromegaly reported si...